Company / Return on Assets (ROA)
Theravance Biopharma, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
21.8%
FY2025
5-year range
-53.2% / 21.8%
FY2021-FY2025
Trend
+236.9%
vs FY2024
Sector context
#10 of 213
Health Care
What the data says
Return on Assets (ROA) changed +237% YoY in FY2025, a notable deviation from the 9-year average annual change of +18%.
Based on SEC 10-K filings.
21.8% in FY2025 with a 5-year CAGR of +81.1%. Top quartile in the Health Care sector.
Improved from -14.4% to 21.8% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +67.6pp
- 5-Year Change
- +81.1pp
- 10-Year Change
- -
Sector benchmark
Top 5% in Health CareTop 5% of 213This company 21.8% Sector average -24.1%
▼
+190.4% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) increased 236.9% year-over-year.
- Currently 45.9pp above the Health Care sector average.
- Lowest return on assets (roa) in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 21.8% | +236.9% |
| FY2024 | -15.9% | -10.2% |
| FY2023 | -14.4% | +68.4% |
| FY2022 | -45.8% | +14.0% |
| FY2021 | -53.2% | +10.2% |
| FY2020 | -59.3% | +15.1% |
| FY2019 | -69.8% | -105.1% |
| FY2018 | -34.0% | +47.4% |
| FY2017 | -64.7% | -116.8% |
| FY2016 | -29.8% | +42.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026